Re: Suppressing c-FOS expression by G-quadruplex ligands inhibits osimertinib-resistant non-small cell lung cancers

J Natl Cancer Inst. 2023 Nov 8;115(11):1427-1428. doi: 10.1093/jnci/djad167.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Acrylamides / pharmacology
  • Acrylamides / therapeutic use
  • Aniline Compounds / pharmacology
  • Aniline Compounds / therapeutic use
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Carcinoma, Non-Small-Cell Lung* / metabolism
  • Cell Line, Tumor
  • Drug Resistance, Neoplasm / genetics
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / metabolism
  • Mutation
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • osimertinib
  • Acrylamides
  • Aniline Compounds
  • Protein Kinase Inhibitors